Intravitreal Injection of Triamcinolone Acetonide in Retinitis

Intravitreal Injection of Triamcinolone Acetonide in Retinitis Pigmentosa with cystoids macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104266293N1

Enrollment

161

Registered

2011-06-24

Start date

2007-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cystoids macular edema (CME) secondary to retinitis pigmentosa (RP).

Interventions

Intravitreal injection of 4mg Triamcinolon in 0.1cc were done only once using a 29 gauge needle at 3.5mm posterior to the limbus. Complete eye examinations including best corrected visual acuity (BCVA

Treatment - Other

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of RP based on paraclinic tests Exclusion criteria: one-eyed patients, history of glaucoma, any opacity in media and history of intraocular surgery

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: 3 weeks, 3 months and 6 months after the injection. Method of measurement: snellen chart.	—

Secondary

Measure	Time frame
Macular thickness and angiographic changes. Timepoint: 3 weeks, 3 and 6 months after the injection. Method of measurement: Slit lamp examination, fundoscopy and OCT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Riazi Esfahani

vice-chancellor of Farabi eye hospital, TUMS

Info@farabihospital.com+98 215540000314

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026